

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently Amended) Drug-containing sustained release ~~microparticles~~ microparticle preparation of a drug other than human growth hormone characterized in that a drug other than human growth hormone and the water-soluble bivalent metal compound are absorbed to a zinc-containing porous hydroxyapatite which is formed by partially substituting calcium atoms of porous hydroxyapatite with zinc characterized by comprising a drug other than human growth hormone and a porous apatite derivative.
2. (Cancelled)
3. (Cancelled)
4. (Currently Amended) The drug-containing sustained release ~~microparticles~~ microparticle preparation of a drug other than a human growth hormone accordingly to claim 1, characterized in that a number of atoms of zinc contained in the zinc-containing porous hydroxyapatite is 0.1 to 2.0 relative to 10 atoms of calcium of the porous hydroxyapatite according to claim 3, characterized in that the porous apatite derivative has a zinc substitution rate or zinc content rate of 0.1 to 2.0.
5. (Cancelled)
6. (Currently Amended) The drug-containing sustained release ~~microparticles~~ microparticle preparation of a drug other than a human growth hormone according to claim [[5]] 1, characterized in that the water-soluble bivalent metal compound is zinc chloride or zinc acetate.

Applicant : Yutaka Mizushima

Appln. No. : 10/559,512

Page -4-

7-12. (Cancelled)

13. (New) The drug-containing sustained release microparticle preparation of a drug other than a human growth hormone according to claim 1, characterized in that the content of the drug other than human growth hormone in the zinc-containing porous hydroxyapatite is from 2% to 30% by weight.